Eagle Prepares Clinical Trials of New Form of Fulvestrant to Treat ER-positive Breast Cancer

Eagle Prepares Clinical Trials of New Form of Fulvestrant to Treat ER-positive Breast Cancer
Eagle Pharmaceuticals is preparing a pilot study that may pave the way for a pivotal clinical trial evaluating its new formulation of fulvestrant as a treatment for estrogen receptor (ER)-positive breast cancer. The company believes its new formulation will block estrogen receptors more effectively than AstraZeneca's original formulation, approved as Faslodex for some hormone receptor (HR)-positive breast cancers. “The opportunity to develop a new treatment option that has the potential to better address the epidemic of breast cancer affecting millions of women in the U.S. and worldwide is an important priority for Eagle,” Scott Tarriff, CEO of Eagle Pharmaceuticals, said in a press release. “If successful, the Eagle product could provide a meaningful improvement and a new option to treat this breast cancer patient population,” he added. Fulvestrant is a form of hormone therapy for breast cancer. It works by selectively blocking estrogen receptors, halting that hormone’s effect on tumor cells. As a consequence, it slows or stops the growth of HR-positive breast cancers, which depend on estrogen to proliferate. Faslodex is approved for HR-positive advanced breast cancer in women who have been through menopause, including those who have not used hormone therapy and those whose cancer progressed after taking a hormonal treatment. Is is also indicated as an add-on treatment for women whose HR-positive breast cancer has sp
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.